

The Most Powerful Name In Corporate News and Information

**Genmed Holding Corp. is Focused on Being the Leading Worldwide
Low Cost Producer of Generic Pharmaceutical Products**



**Healthcare
Generic Drugs
(GENM-OTC: BB)**



**Erwin R. Bouwens
Chairman, President and CEO**

BIO:

Mr. Bouwens is the CEO and founder of the Company. He has spent the last three years securing a relationship with Atabay, developing the current management team and making inroads with major distribution networks to disperse generic drugs. Besides his position as CEO in GENM,

Mr. Bouwens currently holds also a position in De Witte Raaf, which he incorporated along with Dr. Meijer in 2002, a occupational health care service company in the Netherlands offering its services to 500+ employee companies in the Netherlands, with 25 occupational health doctors and working with the 50 largest companies in the Netherlands.

Company Profile:

Genmed Holding Corp. (GENM:OTCBB), through its subsidiary, Genmed B.V., engages in the production and distribution of generic drugs directly to retail chains worldwide. General practitioners, specialists, and hospitals use the generic drugs. The company's primary product is Paracetamol (acetaminophen), a generic form of Tylenol. It has distribution contracts with retail chains in the United Kingdom and The Republic of Ireland and is seeking contracts with retail chains and government agencies and multi-national corporations. The company has distribution licenses in the Netherlands, Belgium, Luxembourg, the United Kingdom, Ireland, Germany, and France, as well as other countries located outside the European Union to supply generic drugs to retail chains.

**Interview conducted by:
Lynn Fosse, Senior Editor
CEOCFOinterviews.com**

CEOCFO: Mr. Bouwens, what was your vision when you founded the company?

Mr. Bouwens: I founded the company about five or six years ago, to take advantage of the growing generic medicine business. I saw that there were a lot of affordable but poor

quality products on the market, coming out of India and China, so my staff and I figured that we could do better. We found a Dutch company called Derking that could help us; Derking is a manufacturer. During that process we found out that we could manufacture our products in low labor cost countries and at the same time meet the strict European rules. One of these rules says that the purity of the working ingredient must be at least 96%.

CEOCFO: What type of medications is Genmed doing today and why these particular ones?

Mr. Bouwens: We started in Europe with the sales of acetaminophen know in the US under the brand name Tylenol, at the moment we are working on a second medication called Ibuprofen. Furthermore we identified about more 70 products that want to register and market across Europe.

CEOCFO: Where and how are you selling the products that you have on the market now?

Mr. Bouwens: 99% of our market is in Europe. We ship, directly from our factories, to the major European distributors and retail chains. So in most cases, we skip the wholesales, thus bringing the product directly to big supermarket chains or directly to big pharmacy chains. That is the big difference between us, and most of the competitors.

CEOCFO: Are there particular name brands or are your customers putting it under their own brand?

Mr. Bouwens: Normally we want to push our own generic brand, but if there is a large quantity, we will make

a private label for them. Therefore, it is up to our customer.

CEO CFO: Is there much competition in the generic area?

Mr. Bouwens: There is a lot of competition. At the moment most of the Tylenol comes from India and China. But we have seen that, some of these major companies from these countries have lost their licenses in Europe, because of contamination in the end product or because there were not enough active ingredients in the pills. For example, the law says the purity of the active ingredient has to be at least 96% and these companies do not meet this standard. Due to our strict quality procedures can deliver a product that is consistent and always meets the EU criteria, so we are different in that.

CEO CFO: Does the public pay much attention to this or is it still kind of under the radar?

Mr. Bouwens: It is a bit under the radar, although we all can recall last years baby milk contamination scandal in China. Therefore, we have quality and safety personnel on our own staff. We hired them so that we are always on the safe side and never bring to the market products with poor quality or less active ingredients. This is how we work with it.

CEO CFO: In what countries does Genmed have distribution agreements?

Mr. Bouwens: At the moment we completed an agreement for the in the U.K. and Ireland with a very large company, and we are in full process to close a deal in France with a large company.

CEO CFO: Genmed has hired Eric Roberts to be a spokesperson for your products; please tell us about this relationship.

"I founded the company about five or six years ago to take advantage of the growing generic products business. I saw that there were a lot of poor quality products coming out of India and China... Then we found out that we could bring the active ingredients of some generic products to the higher percentage of about 97% and we would do it a bit cheaper. We started in Europe with Tylenol, and the second medication that we are working on at the moment is Ibuprofen. Then we have about 70 products for us to register in Europe."
- Erwin R. Bouwens

Mr. Bouwens: We asked Oscar nominated actor Eric Roberts to be our spokesman and because of his medical history. He liked our profile of making better drugs more available and a cheaper.

CEO CFO: What is the financial picture like for Genmed Holding today?

Mr. Bouwens: We report every quarter and most of it is in the filings, which are available on the internet.

CEO CFO: What is the plan for Genmed over the next year or so?

Mr. Bouwens: In the next year, we will launch in approximately three other countries, which will be Italy, Spain and Poland. The second thing we will do is, launch two new products, which will be Ibuprofen and Diclofenac.

CEO CFO: In closing, why should potential investors pay attention to Genmed?

Mr. Bouwens: Potential investors should pay attention because at this moment the stock is very low but the next six months we expect to announce new, big customers. And remember, if we do a contract with a new customer, we will sign an agreement for five years, so for one country for five years. Our overhead is very low and the way you transport products through

Europe is very economical, so we will be very competitive in the generic market space.

CEO CFO: So people should pay attention to Genmed!

Mr. Bouwens: Yes, they should!

